GHK-Cu for Hair Loss: What the Evidence Actually Shows

GHK is a tripeptide, three amino acids linked together, that occurs naturally in human plasma, saliva, and urine. GHK binds copper, and the copper-bound form, GHK-Cu, is what fills the serums and vials.

Its research history sits mostly in wound healing and skin repair, according to a 2015 review of GHK research, and it built its reputation in skin care. What matters here: this peptide's resume is skin and wounds, not hairlines. The scalp products came later, and so did the claims.

The pitch follows a chain of logic, and the chain has weak links. The 2015 review by Pickart and colleagues reports wound-healing effects in tissues including hair follicles, effects in animals, and cosmetic skin effects. Those are wound-healing and animal findings; the review reports no randomized trials of GHK-Cu for male pattern hair loss.

You should also know that the review's authors work for a company that sells GHK products. That does not make the science wrong. It means you weigh it the way you would any seller's research summary.

The gap between effects in lab tissue and regrowth on a 45-year-old scalp is where a whole industry lives.

Put the two columns side by side. In the first, GHK-Cu for hair: we searched PubMed for randomized, placebo-controlled trials of GHK-Cu for male pattern hair loss and found none. What remains is wound-healing research, animal and cell work, and the marketing leap between them.

In the second, the established treatments. A 2017 systematic review and meta-analysis in the Journal of the American Academy of Dermatology pooled good- and fair-quality randomized trials and found minoxidil, finasteride, and low-level laser light therapy each superior to placebo for male pattern hair loss. The same review notes that minoxidil and finasteride are FDA-approved, and a laser comb device FDA-cleared, for this condition.

The review also notes that male pattern hair loss is driven by dihydrotestosterone (DHT), the potent form of testosterone. A hair-growth claim for GHK-Cu has no comparable human-trial foundation.

This is the line most marketing hopes you never read. Under FDA's rules, whether a product is a cosmetic or a drug depends on its intended use. A cosmetic can be marketed to improve appearance. A claim to restore hair growth is FDA's own example of a claim that makes a product a drug.

Hold that against one fact: GHK-Cu is not an FDA-approved treatment for hair loss. So if a cosmetic with GHK-Cu promises regrowth, it is making a drug claim without drug approval. That is not a technicality; it tells you the claim has not cleared the bar the proven treatments cleared.

FDA keeps a list of bulk drug substances that may present significant safety risks in compounding. As of April 22, 2026, that list includes GHK-Cu for injectable routes as nominated but withdrawn. FDA states that compounded injectable GHK-Cu may pose a risk of immune reactions due to aggregation and peptide-related impurities, and that there are limited data in humans to inform safety.

The peer-reviewed literature lands on the same uncertainty. A 2026 review in Sports Medicine covering GHK-Cu among unapproved peptides found rigorous human safety data scarce, with potential for serious harm. Injectable GHK-Cu is where the hype outruns the safety file by the widest margin.

Start with a dermatologist. A clinician can tell you what kind of hair loss you actually have. Male pattern hair loss has a specific driver, DHT, and treatments with trial evidence. Getting a diagnosis early gives you and your doctor more options.

Minoxidil, finasteride, and low-level laser therapy each beat placebo in randomized trials, with FDA approval or clearance noted in the same review. Which fits you is a decision for you and your clinician. Then hold every new claim to the filter below.